Physician profile
Taylor A Long
NPI 1730873159
$1,095.46
in general payments reported to CMS, 2019-2025
15 companies · $434 in 2025
The $434 reported for 2025 was more than what 90% of Pediatrics (Nurse Practitioner) providers received nationally (typical 2025 total: $93.49).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $132 · 2024: $530 · 2025: $434.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,095.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,095.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $177.68 | 2025 | Jornay Pm |
| Merck Sharp & Dohme LLC | $151.97 | 2023-2025 | Vaxneuvance, Gardasil 9, Vaxelis |
| Krystal Biotech INC | $136.45 | 2024 | Vyjuvek |
| Corium, LLC | $110.02 | 2023-2025 | Azstarys |
| Vertical Pharmaceuticals, LLC | $105.47 | 2024-2025 | Relexxii |
| Acadia Pharmaceuticals INC | $80.56 | 2024 | Daybue |
| Pfizer INC. | $77.19 | 2024 | |
| Ironshore Pharmaceuticals INC. | $56.42 | 2023-2024 | Jornay Pm |
| Avion Pharmaceuticals | $37.26 | 2023 | Methylphenidate Hydrochloride |
| Glaxosmithkline, LLC. | $36.91 | 2025 | Bexsero |
| Seqirus USA INC | $32.09 | 2025 | Flucelvax |
| Neos Therapeutics, LP | $30.53 | 2024 | Cotempla Xr-Odt |
| Kaleo, INC. | $25.04 | 2023 | Auvi-Q |
| Astrazeneca Pharmaceuticals LP | $19.71 | 2024 | Flumist Quadrivalent |
| Biomarin Pharmaceutical INC. | $18.16 | 2025 | Voxzogo 1.2mg |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylor Long listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.